By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its potential one-time gene therapy for the treatment of so-called wet AMD. “We believe that there […]
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles